Haematologica, Vol 92, Issue 4, 469-477 doi:10.3324/haematol.10723
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Igreja, C.
Right arrow Articles by Dias, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igreja, C.
Right arrow Articles by Dias, S.
Related Collections
Right arrowRelated Article

Malignant Lymphomas

Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients

Cátia Igreja, Margarida Courinha, Ana Sofia Cachaço, Teresa Pereira, José Cabeçadas, Maria Gomes da Silva, Sérgio Dias

From the Angiogenesis Laboratory, Centro Investigação em Patobiologia Molecular (CIPM), Instituto Português de Oncologia Francisco Gentil, Centro de Lisboa (IPOFG), Lisboa, Portugal (CI, MC, ASC, SD); Serviço de Anatomia Patológica, IPOFG (TP, JC); Departamento de Hemato-Oncologia, IPOFG (MGDS); Instituto Gulbenkian de Ciência, Oeiras, Portugal (SD); Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal (SD).

Correspondence: Sérgio Dias, Angiogenesis Laboratory, CIPM, Instituto Português de Oncologia Francisco Gentil, Centro Regional de Oncologia de Lisboa, Rua Professor Lima Basto, 1099-023 Lisboa, Portugal. E-mail: sergidias{at}ipolisboa.minsaude.pt

Background and Objectives: Endothelial progenitor cells (EPC) have been proven to be essential for tumor angiogenesis and growth in animal tumor models. However, the involvement and relevance of EPC in human cancers remain poorly studied. We, therefore, investigated the presence, differentiation potential and molecular characteristics of EPC in lymphoma patients.

Design and Methods: EPC (CD133+CD34+KDR+ cells) were detected in peripheral blood (PB) and lymph node (LN) biopsy samples of 70 lymphoma patients by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. Magnetically isolated EPC (PB and LN-derived) were tested, in vitro, for endothelial differentiation potential and RNA was collected to study their gene expression profiles by Affymetrix oligonucleotide arrays. Lymphoma patients were classified according to disease aggressiveness (indolent vs aggressive lymphoma) and their data (tumor angiogenesis, tumor stage and clinical treatment) were related to the presence or absence of EPC in the circulation or in tumor samples.

Results: Circulating EPC (CEPC) were more frequent in patients than in healthy controls and more frequent in younger patients than in older patients and in those with aggressive lymphomas. The levels of CEPC decreased in patients with complete response to treatment, but were sustained or increased in the non- or partial- responders to lymphoma therapy. Notably, EPC in the LN (LN-EPC) were more frequently detected than CEPC; LN-EPC were detected in vascular structures and also in the stroma, and after isolation differentiated into endothelial cells in vitro. The presence of LN-EPC correlated with lesion size and with increased angiogenesis in indolent lymphomas. CEPC and LN-EPC share endothelial markers but can be identified and quantified separately, since they express different CD133 isoforms. Gene expression profiling of isolated LN-EPC revealed the expression of pro-angiogenic and tumor growth factors that may influence lymphoma growth.

Interpretation and Conclusions: EPC are present in the circulation and in tumor samples from patients with non-Hodgkin’s lymphoma. Since there are relationships between EPC and various characteristics of lymphoma, our research has demonstrated the clinical and biological relevance of studying CEPC and LN-EPC in lymphoma patients.

Key words: endothelial progenitors, non-Hodgkin’s lymphoma, molecular characterization.


Related Article

Endothelial progenitor cells in non-Hodgkin’s lymphoma
Yasuhiro Oki, Anas Younes
Haematologica 2007 92: 433-434. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 QJMHome page
M.R. Goldstein, L. Mascitelli, and F. Pezzetta
Primary prevention of cardiovascular disease with statins: cautionary notes
QJM, November 1, 2009; 102(11): 817 - 820.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc., March 1, 2009; 20(3): 413 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt, S. Joel, F. Donate, C. Hayward, S. Reich, et al.
Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors
Clin. Cancer Res., November 15, 2008; 14(22): 7526 - 7534.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
Y. Oki and A. Younes
Endothelial progenitor cells in non-Hodgkin's lymphoma
Haematologica, April 1, 2007; 92(4): 433 - 434.
[Full Text] [PDF]